Panzyga (Human Normal Immunoglobulin)

Panzyga is an immunoglobulin therapy indicated for disorders that involve antibody deficiency or dysregulation:

• Primary immunodeficiency diseases (PID): provides supplemental immunoglobulin to reduce infection frequency.
• Chronic inflammatory demyelinating polyneuropathy (CIDP): helps maintain functional ability and may reduce relapse risk.
• Multifocal motor neuropathy (MMN): offers symptomatic improvement and supports motor function.
• Immune thrombocytopenia (ITP) refractory to first‑line therapy: increases platelet counts in selected patients.
• Kawasaki disease with coronary artery involvement: supplies passive immunity that may modulate vascular inflammation.

• Panzyga contains pooled human IgG antibodies that bind a broad spectrum of pathogens and immune targets. By supplementing circulating IgG, it restores humoral immunity, neutralises toxins, and modulates Fc‑mediated immune responses, thereby reducing inflammatory activity and preventing infection in patients with antibody deficiencies.

Panzyga, like other intravenous immunoglobulin products, may be associated with a range of adverse reactions.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Fever or chills: typically occurring during or shortly after infusion.
• Nausea or vomiting: usually mild and self‑limiting.
• Fatigue or malaise: resolves within hours to a day.
• Injection site reactions: erythema, warmth or swelling at the infusion site.
• Hypertension or transient blood pressure changes.

Serious or Rare Side Effects

• Thromboembolic events: including deep‑vein thrombosis or pulmonary embolism.
• Renal impairment: acute kidney injury, particularly with high‑dose regimens.
• Aseptic meningitis: severe headache with meningeal signs.
• Hemolytic anemia: due to anti‑red‑cell antibodies.
• Anaphylaxis or severe hypersensitivity reactions.
• Transfusion‑related acute lung injury (TRALI).

When using Panzyga, clinicians should consider several safety measures:

• Assess renal function: evaluate baseline creatinine and monitor during therapy.
• Screen for thrombotic risk: review patient history of clotting disorders.
• Monitor blood pressure: observe for hypertension during infusion.
• Evaluate for IgA deficiency: patients with anti‑IgA antibodies may be at higher risk of anaphylaxis.
• Adjust infusion rate: slower rates can reduce incidence of headache and chills.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Panzyga may interact with other medicines, requiring attention to dosing and monitoring:

Major Interactions (Avoid)

• Live vaccines: concurrent administration can diminish vaccine efficacy and increase adverse event risk.
• High‑dose aspirin or NSAIDs: may increase bleeding tendency when combined with immunoglobulin.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin, DOACs): immunoglobulin can affect coagulation parameters; monitor INR or relevant labs.
• Diuretics: potential for volume overload; assess fluid status.
• Immunosuppressants (e.g., rituximab, cyclophosphamide): may alter infection risk profile.
• ACE inhibitors: monitor for hypotension during infusion.
• Corticosteroids: may mask early signs of infection; observe closely.